Biogen (Nasdaq: BIIB) and Denali Therapeutics (Nasdaq: DNLI) reported that BIIB122 (DNL151), a selective small-molecule LRRK2 inhibitor, failed to slow disease progression in early-stage Parkinson's disease in the Phase IIb LUMA study. The drug candidate missed both primary and secondary endpoints, with the two firms consequently deciding to draw to a close the compound's development program in idiopathic Parkinson's disease.
The LUMA study was a randomized, double-blind, placebo-controlled trial enrolling 648 adults aged 30 to 80 with early-stage Parkinson's disease, including participants with and without a pathogenic LRRK2 variant. Participants received BIIB122 or placebo for a minimum of 48 weeks and up to 144 weeks. The primary endpoint — time to confirmed worsening on the combined MDS-UPDRS Parts II and III score — showed no difference versus placebo, and secondary endpoints were similarly negative. Exploratory biomarker data offered the study's only mechanistic signal: BIIB122 achieved greater than 90% kinase inhibition of peripheral LRRK2 (phosphoserine 935), and a cerebrospinal fluid sub-study recorded approximately 30% reduction in phosphorylated Rab10, a downstream marker of LRRK2 activity. Drug exposure in blood and CSF was maintained across the study duration. The compound was generally well tolerated, with no new safety concerns reported.
The LUMA failure narrows the LRRK2 inhibitor field further. Denali's earlier LRRK2 inhibitor, DNL201, was discontinued after Phase I due to hepatotoxicity, and BIIB122 had been advanced in part because of its cleaner safety profile. The biomarker data from LUMA confirm that BIIB122 engaged its target at the molecular level — raising questions about whether LRRK2 inhibition is sufficient to modify disease course in unselected idiopathic Parkinson's disease, or whether the patient population was too heterogeneous to detect an effect. Cross-trial comparisons are limited, but the pattern echoes earlier failures in alpha-synuclein-targeting approaches. Denali will independently continue the Phase IIa BEACON study in genetically confirmed LRRK2 variant carriers, with data anticipated in the first half of 2027 — the remaining test of whether pathway-matched patient selection can rescue the mechanism.
This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/
Spot something wrong? Report an issue with this article